CDXS - Codexis, Inc.
| Previous Close | 13.31 |
| Open | 13.32 |
| Bid | 13.67 x 800 |
| Ask | 13.69 x 800 |
| Day's Range | 13.29 - 13.81 |
| 52 Week Range | 12.68 - 23.05 |
| Volume | 116,994 |
| Avg. Volume | 448,520 |
| Market Cap | 798.346M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.50 |
- Business Wire
Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit
Codexis, Inc. , a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco, Oct.
- GlobeNewswire
Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 26, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor.
- Simply Wall St.
Is Codexis, Inc.'s (NASDAQ:CDXS) CEO Pay Justified?
John Nicols became the CEO of Codexis, Inc. (NASDAQ:CDXS) in 2012. First, this article will compare CEO compensation...
- Motley Fool
3 Top Stocks Under $20
Your money can buy more shares of these promising companies thanks to an affordable stock price.
- GuruFocus.com
Codexis Inc (CDXS) President and CEO John J Nicols Bought $133,000 of Shares
President and CEO of Codexis Inc (30-Year Financial, Insider Trades) John J Nicols (insider trades) bought 10,000 shares of CDXS on 08/20/2019 at an average price of $13.3 a share. Continue reading...
- Thomson Reuters StreetEvents
Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Codexis Inc Earnings Call
- Motley Fool
Codexis Rolls Into Second Half Armed with Cash
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
Motley FoolCodexis(CDXS) Q2 2019 Earnings Call Transcript
CDXS earnings call for the period ending June 30, 2019.
- Zacks
Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Codexis Reports Second Quarter 2019 Financial Results
Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., Aug. 06,.
- GlobeNewswire
Codexis to Hold Second Quarter 2019 Conference Call on August 6
REDWOOD CITY, Calif., July 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results.
- GlobeNewswire
Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives
Codexis, Inc. (CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. “The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets,” said Codexis President and CEO John Nicols.
- Motley Fool
Is Codexis a Buy?
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
- GlobeNewswire
Codexis to Present at the Jefferies 2019 Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the Jefferies 2019 Global.
- Simply Wall St.
Who Has Been Selling Codexis, Inc. (NASDAQ:CDXS) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- GlobeNewswire
Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader
Codexis, Inc. (CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary CodeEvolver® protein engineering platform technology to Novartis to develop novel performance enzymes for use in manufacturing pharmaceutical products. Upon completion of the technology transfer, the CodeEvolver® protein engineering platform will be located at a Novartis site.
- GlobeNewswire
Codexis to Participate at Three Investment Conferences in May
REDWOOD CITY, Calif., May 14, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming.
- Thomson Reuters StreetEvents
Edited Transcript of CDXS earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Codexis Inc Earnings Call
- Motley Fool
Codexis Bags Novartis as Software Customer, Stays Course in First Quarter
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Codexis, Inc. (CDXS)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
Motley FoolCodexis(CDXS) Q1 2019 Earnings Call Transcript
CDXS earnings call for the period ending March 31, 2019.
- Zacks
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 5.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Codexis: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The producer of custom ...
- GlobeNewswire
Codexis Reports First Quarter 2019 Financial Results
Total revenues increase 11% to $15.6 million, product revenue up 30% Recent highlights include Third CodeEvolver® Platform Technology Agreement and Multi-Year Enzyme Supply and.
